Kallisio delivers patient-specific medtech solutions that help oncologists reduce treatment-related toxicity and protect healthy tissue in cancer care. By developing customized technologies tailored to each patient’s anatomy and treatment plan, Kallisio enhances therapy precision and improves outcomes across multiple treatment modalities.

The stentra™ oral stent, an FDA approved 3D-printed patient-specific device, exemplifies this approach. It provides unparalleled protection for Organs-at-Risk (OARs) during head and neck cancer therapy, significantly reducing side effects like oral mucositis. This results in better patient outcomes, enhanced comfort, and improved quality of life during treatment.

Through our commitment to precision, innovation, and patient-centered care, Kallisio transforms oncology treatment, enabling clinicians to deliver safer, more effective therapies while reducing the burden of cancer toxicity.

kallisio,inc.

Org chart

Teams

Offices